https://www.selleckchem.com/products/ca3.html Consequently, there is synergy between our two laboratories. Since this special tribute issue of Aging Research Reviews is dedicated to the career of Dr. Mattson, a review of some aspects of this synergy of lipid peroxidation and its relevance to AD, as well as the role of lipid peroxidation in the progression of this dementing disorder seems germane. Accordingly, this review outlines some of the individual and/or complementary research on lipid peroxidation related to AD published from our two laboratories either separately or jointly. The wearable cardioverter-defibrillator (WCD) was first approved for clinical use in 2002, and is routinely used in select populations at high risk for sudden cardiac death. WCDs are frequently considered as a bridge to definitive therapy or in circumstances where insertion of conventional implantable cardioverter-defibrillators (ICD) is temporarily contraindicated. In this review, we summarize the literature on WCDs. From prospective trials to the first randomized controlled trial with WCD, there is a growing body of evidence that suggests that the WCD is safe and effective. In the first randomized controlled trial of the WCD (VEST Trial), there was no reduction in arrhythmia death but there was a reduction in all-cause mortality. We discuss the mortality impact, rate of inappropriate shocks, compliance, and potential quality of life implications with the WCD. Finally, we present the evidence for WCD use in select populations (e.g., post-myocardial infarction, device extraction), and the current guideline recommendations for WCD use. Familial hypercholesterolemia (FH) is a common genetic cause of elevated low-density lipoprotein cholesterol (LDL-C) due to defective clearance of circulating LDL particles. All FH patients are at high risk for premature cardiovascular disease (CVD) events due to their genetically determined lifelong exposure to high LDL-C levels. However, different rates of